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OBJECTIVE: Hepatitis C virus (HCV) is one of the major
causes of chronic liver disease worldwide but its mor-
bidity is also due to a variety of extra-hepatic manifesta-
tions including mixed cryoglubulinemia, non–Hodgkin
lymphoma, diabetes, porphyria cutanea tarda and lichen
planus. The aims of this study were to conduct a sys-
tematic review and a meta-analysis on the prevalence of
HCV in lichen planus patients and on the prevalence of
lichen planus in chronic HCV infection.
MATERIALS AND METHOD: Bibliographic searches
were conducted in several electronic databases. Pooled
data were analysed by calculating odds ratios, using a
random effects model.
RESULTS AND CONCLUSIONS: Thirty-three studies
comparing the seroprevalence of HCV in lichen planus
patients and six reporting the prevalence of lichen planus
in patients with HCV infection were included in the meta-
analysis. The summary estimate showed that LP patients
have significantly higher risk (odds ratio 4.85; 95% confi-
dence interval 3.58–6.56) than controls of being HCV
seropositive. A similar odds ratio of having lichen planus
was found among HCV patients (4.47; 95% confidence
interval 1.84–10.86). Sub-analyses indicated that vari-
ability of HCV ⁄ lichen planus association seemed only
partially depending on geographic effect.
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Introduction
Hepatitis C virus (HCV) is presently considered as the
main etiologic agent of both blood-borne and sporadic
non-A and -B hepatitis, and is one of the major causes
of chronic liver disease worldwide. However, morbidity
associated with HCV infection is due not only to the
sequelae of chronic liver disease, but also to a variety of
extra-heaptic manifestations (EHM). According to a
recent review, mixed cryoglubulinemia is the only EHM
in which the association with HCV has been demon-
strated by both epidemiological and pathogenetic evi-
dences, while diseases strongly suspected to be linked to
HCV include B-cell non-Hodgkin lymphoma, monoclo-
nal gammopathies, porphyria cutanea tarda and lichen
planus (LP) (Zignego et al, 2007).
Lichen planus is a relatively common disorder of the
stratiﬁed squamous epithelia frequently involving the
oral cavity exclusively (Eisen et al, 2005).
It is likely that LP represents a sterotype-cell mediated
reaction to a variety of extrinsic antigens, altered self-
antigens, or super antigens. Among the extrinsic factors,
several infective agents, including some viruses and
Helicobacter pylori, have been linked with LP but
sometimes on the basis of equivocal data (Lodi et al,
2005; De Vries et al, 2006).
A possible link between hepatitis viruses and LP has
been suggested by the frequent association between LP
and chronic liver disease (CLD) in Mediterranean
patients (Carrozzo and Gandolfo, 2003) but no patho-
genic correlation could be found until HCV assays
became available. The risk of chronic liver disorders in
LP patients is in fact independent from alcohol con-
sumption, and is still signiﬁcantly high after adjustment
for a positive hepatitis B surface antigen (HBsAg)
reaction (GISED, 1990). Markers of past hepatitis B
virus (HBV) infection [antibodies to hepatitis B surface
antigen (HBsAb) and to hepatitis B core antigen
(HBcAb)] have been reported in Spanish and Italian
patients with LP (Ayala et al, 1986; Delolmo et al, 1990;
Carrozzo et al, 1996), but with prevalence quite close the
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average ﬁgure in the Mediterranean area. Moreover, the
recently discovered viruses, hepatitis G virus or TTV,
are not associated with LP (Nagao et al, 1997; Lodi
et al, 2000; Bez et al, 2001; Rodriguez-Inigo et al, 2001).
When sensitive HCV diagnostic tests became avail-
able, a great amount of case reports (Carrozzo, 2008),
cohort and controlled studies suggested a link between
LP and HCV infection. A systematic review investi-
gating HCV seropositivity in LP patients was published
in 2004 (Lodi et al, 2004) and more than 20 controlled
studies were published thereafter (Bokor-Bratic, 2004;
Campisi et al, 2004; Chung et al, 2004; Denli et al,
2004; Harman et al, 2004; Karavelioglu et al, 2004;
Asaad and Samdani, 2005; Dervis and Serez, 2005;
Guerreiro et al, 2005; Laeijendecker et al, 2005; Luis-
Montoya et al, 2005; Rahnama et al, 2005; Das et al,
2006; Sulka et al, 2006; Ali and Suresh, 2007; Amer et al,
2007; de Mattos Camargo et al, 2007; Ghaderi and
Makhmalbaf, 2007; Giuliani et al, 2007; Yarom et al,
2007). Moreover, the frequency of LP in patients with
HCV infection has never been reviewed systematically.
In recent reviews devoted to HCV-EHM, conﬂicting
statements have been made, some supporting and others
discharging the link between LP and such viral infection
(Sene et al, 2004; Ali and Zein, 2005; Palekar and
Harrison, 2005; Sterling and Bralow, 2006; Galossi et al,
2007; Okuse et al, 2007; Zignego et al, 2007; Carrozzo,
2008) but literature was rarely reviewed with a system-
atic approach.
Furthermore, IFN-a and ribavirin may cause or
exacerbate some muco-cutaneous disorders (Berk et al,
2007), including LP, sometimes leading to anti-HCV
treatment withdrawal (Protzer et al, 1993). As a result, it
is diﬃcult to determine whether LP results from HCV,
IFN-a ⁄ ribavirin, both or neither. On the other hand,
there are also some concerns about the inclusion of LP
patients in clinical trial of IFN-a therapy (Berk et al,
2007).
The aim of our study was to systematically review
epidemiological data on the association between HCV
infection in LP. The two null hypotheses of our study
were that (ii) there is no diﬀerence between the propor-
tion ⁄number of anti-HCV seropositive subjects in
patients aﬀected by LP compared with control groups,
against the alternative hypothesis of a diﬀerence, and
(ii) there is no diﬀerence between the proportion ⁄ num-
ber of subjects aﬀected by LP in patients HCV
seropositive compared with control groups, against the
alternative hypothesis of a diﬀerence.
All along the text the term LP has been used
generically to indicate both skin and oral LP (OLP).
When a more speciﬁc indication was opportune, the
more precise terminology of skin or cutaneous LP and
OLP was used.
Patients and methods
Criteria for considering studies
Studies addressing the relationship between LP and
HCV seropositivity were considered. We collected either
studies investigating the prevalence of HCV in LP
patients or studies assessing the frequency of LP in HCV
seropositive and ⁄or infected subjects. Studies were
eligible for the inclusion in the meta-analysis when they
fulﬁlled the following criteria:
1. analytical study design as indicated by Grimes and
Schulz (Grimes and Schulz, 2002), i.e. an observa-
tional study with a comparison or control group;
2. diagnosis of LP based on clinical and histological
features;
3. HCV seropositivity based on serological test for
circulating anti-HCV antibodies
Exclusion criteria were the following:
1. Studies involving patients with HCV and HIV
co-infection
2. Studies where HCV could not be excluded from other
causes of liver disease
3. Studies using references data or data from blood
donors banks or historical controls
4. Duplicate studies (studies originating from the same
subjects by the same investigators but published in
diﬀerent journals)
5. Articles providing insuﬃcient information to calcu-
late the OR
Search strategy for identiﬁcation of studies
To identify relevant literature, bibliographical searches
were performed in PubMed (January 1966 to November
2007), EMBASE (January 1988 to November 2007)
CINAHL (January 1982 to November 2007) and
SCOPUS (January 1960 to November 2007) databases
using the following terms: Hepatitis C’, Hepacivirus’,
HCV’, lichen planus’ and lichen*’. To identify addi-
tional studies, references lists of previously identiﬁed
published papers were searched and the World Wide
Web was searched by means of a search engine (http://
www.google.com). The title and abstract of each article
resulting from the literature search were independently
reviewed by two investigators and when the article was
considered relevant, the full report was obtained.
Disagreements about eligibility were resolved by con-
sensus with a third reviewer. Articles published in any
language were included.
Methods of the review
Selection of studies and assessment of study quality.
Every study included was assessed on the basis of:
(i) characteristics of the study group (consecutive,
unselected patients); (ii) appropriateness of the control
group: subjects belonging to the control group must not
diﬀer importantly from those of the study group (sex
and age must be matched, subjects of the control group
must be selected from the study base); and
(iii) prospective design (i.e. data and sera collected on
purpose). Each of these criteria was rated as met’,
unmet’ or unclear’. The global validity of the study was
assessed using three categories: (i) low risk of bias: all
criteria met; (ii) moderate risk of bias: one or two
criteria unclear; and (iii) high risk of bias: at least one
criterion unmet or three criteria unclear. The critical
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appraisal of the studies was carried out without blinding
the name of the authors, institutions or journal Final
decision about inclusion or exclusion was made by
mutual agreement
Data about the study, its eligibility, validity, design
and outcome information, were recorded on an abstrac-
tion form.
Data extraction and statistical analysis. For each study,
data on the numbers of subjects of the study group and
the control group with a positive outcome (HCV
seropositivity among LPs, and LP among HCV sero-
positives), were extracted. For each study an OR and
95% CI was calculated. Where absence of events in one
of the groups caused problems with computation of OR,
0Æ5 was added to all values for that study, except when
absence of events involved both study and control
groups, in which case OR was undeﬁned (Deeks et al,
2001). Heterogeneity was measured calculating I2, a
statistic for quantifying inconsistency among studies.
However, as heterogeneity among studies was expected
on the basis of a large variability in HCV prevalence
across diﬀerent countries, a random eﬀect was used to
calculate the summary estimate.
Subgroup analysis was undertaken for geographical
area, patients with oral lesions, age, studies excluding
lichenoid reactions and researches including a conﬁr-
matory HCV test further to the screening one. Sensitiv-
ity analysis was undertaken excluding studies of lower
methodological quality (i.e. studies at moderate and
high risk of bias). To investigate potential for publica-
tion bias we checked for asymmetry of the funnel plot of
the OR of the included studies. The statistical analysis
was conducted using RevMan5, a copyrighted freeware
developed by the Cochrane Collaboration, for preparing
and maintaining reviews (http://www.cochrane-net.org/
revman).
Results
From 447 articles identiﬁed with diﬀerent search strat-
egies, 97 potentially eligible studies were found, of them
70 studies worldwide investigated HCV seroprevalence
among LP patients (Table 1) and 27 of them investi-
gated the frequency of LP in patients with chronic HCV
infection met the criteria to be included in the review
(Figure 1).
HCV prevalence among LP patients
The overall prevalence of HCV in LP patients according
to the 70 studies involving 6378 patients was 22.3%,
with a high variability among and within countries
(Table 1). Among these studies, 33 met our inclusion
criteria and were considered for the systematic review
(Cribier et al, 1994; Santander et al, 1994; Bellman et al,
1995; Gimenez-Arnau et al, 1995; Tanei et al, 1995;
Carrozzo et al, 1996; Sanchez-Perez et al, 1996; Dupin
et al, 1997; Imhof et al, 1997; Serpico et al, 1997; Bagan
et al, 1998; Ilter et al, 1998; Ingafou et al, 1998;
Mignogna et al, 1998; Ibrahim et al, 1999; Issa et al,
1999; Tucker and Coulson, 1999; Kirtak et al, 2000;
Table 1 Studies investigating HCV seroprevalence in groups of lichen
planus patients
Reference
Lichen planus
patients
Number of
HCV+ subjects
Ali and Suresh, 2007 40 0
Amer et al, 2007 30 21
Asaad and Samdani, 2005 114 30
Bagan et al, 1994 187 28
Bagan et al, 1998 100 23
Beaird et al, 2001 24 4
Bellman et al, 1995 30 7
Bokor-Bratic, 2004 48 0
Campisi et al, 2004 859 238
Carrozzo et al, 1996 70 19
Chainani-Wu et al, 2004 31 14
Chuang et al, 1999 22 12
Chung et al, 2004 32 14
Cribier et al, 1994 52 2
Daramola et al, 2002 57 9
Das et al, 2006 104 2
del Olmo et al, 2000 169 36
de Mattos Camargo et al, 2007 50 1
Denli et al, 2004 140 7
Divano et al, 1992 46 11
Divano et al, 1994 56 13
Dupin et al, 1997 102 8
Dupond et al, 1998 28 8
Egan and Zone, 1997 29 4
Eisen, 2002 195 0
Erkek et al, 2001 54 7
Figueiredo et al, 2002 68 6
Gandolfo et al, 1994 105 10
Garg et al, 2002 64 0
Ghaderi and Makhmalbaf, 2007 73 3
Ghodsi et al, 2004 146 7
Gimenez-Arnau et al, 1995 25 11
Gimenez-Garcia and
Perez-Castrillon, 2003
101 9
Giuliani et al, 2007 79 9
Grote et al, 1998 24 1
Guerreiro et al, 2005 66 5
Harman et al, 2004 128 8
Ibrahim et al, 1999 43 9
Ilter et al, 1998 75 0
Imhof et al, 1997 84 13
Ingafou et al, 1998 55 0
Issa et al, 1999 34 2
Karavelioglu et al, 2004 41 2
Khaja et al, 2006 21 52
Kirtak et al, 2000 73 5
Kirtschig et al, 2005 44 0
Klanrit et al, 2003 60 4
Laeijendecker et al, 2005 100 0
Lodi et al, 2004 303 58
Luis-Montoya et al, 2005 36 1
Mahboob et al, 2003 184 43
Mignogna et al, 1998 263 76
Mignogna et al, 2002 600 165
Nagao et al, 1995 45 28
Narayan et al, 1998 75 2
Parodi et al, 1996 61 13
Prabhu et al, 2002 65 0
Rahnama et al, 2005 66 1
Rebora et al, 1992 79 21
Rossi and Colasanto, 2000 100 13
Roy et al, 2000 6 0
Sanchez-Perez et al, 1996 78 16
Santander et al, 1994 50 19
Sata et al, 1996 45 28
Serpico et al, 1997 100 36
Schmitt et al, 1995 32 11
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Beaird et al, 2001; Erkek et al, 2001; Daramola et al,
2002; Garg et al, 2002; Gimenez-Garcia and Perez-
Castrillon, 2003; Klanrit et al, 2003; Bokor-Bratic, 2004;
Harman et al, 2004; Lodi et al, 2004; Luis-Montoya
et al, 2005; Rahnama et al, 2005; Das et al, 2006; Ali and
Suresh, 2007; Ghaderi and Makhmalbaf, 2007; Yarom
et al, 2007).
Characteristics of the included studies. The main charact-
eristics of the 33 included studies are presented in Table 2.
Nineteen out of 33 studies were fromEuropean countries,
two fromUSA, two fromAfrica, six from Asia, two from
Middle East and two from South America. Two studies
were written in a language diﬀerent from English: one in
Portuguese and one in Italian.
Eleven included only patients with oral lesions,
which were present in a variable proportion in most
of the other studies. The control group was enrolled
amongst dermatological patients in 12 studies, in one
case some patients with potentially HCV associated
dermatological conditions (porphyria cutanea tarda,
cutaneous vaculitis and prurigo) were excluded, while
another included psoriasis patients only. The other
control groups were formed by dental patients (ﬁve
studies), blood donors (four study), dental health care
workers (two study), healthy subjects (two studies),
patients with unrelated oral keratoses (two study),
surgical patients (two studies), healthy subjects and
dermatological patients (one study), HIV negative
outpatients (one study); in two studies the origin of
control group was not speciﬁed. The serological test
adopted to detect circulating anti-HCV antibodies was
a second generation ELISA in 14 studies and a
third ⁄ fourth generation ELISA in 15; in four cases
the characteristics of the test were not reported.
Positive results were conﬁrmed by means of another
test in 14 studies (Table 2).
Critical appraisal of the included studies. On the basis of
the criteria previously described, nine studies resulted
at low risk of bias, 11 were judged at moderate risk of
bias, and 13 at high risk of bias (Table 2). The ﬁrst
criterion was met in less of half the studies, since study
group was clearly formed by consecutive, unselected
patients with LP in only 15 of the 33 studies. Of the
other two criteria, control group was adequately
selected and matched in 20 cases and the study had a
prospective design in 19. None of the studies published
in form of letter or abstract was judged at low risk of
bias.
Table 1 (Continued)
Reference
Lichen planus
patients
Number of
HCV+ subjects
Tanei et al, 1995 45 17
Tucker and Coulson, 1999 45 0
van der Meij and van der Waal, 2000 55 0
Yarom et al, 2007 62 3
Total 6378 1420 (22.26%)
Studies on HCV prevalence in LP 
patients = 70 
Studies = 48 
Studies included in the 
systematic review = 33 
350 studies were excluded because not relevant 
22 studies were excluded because 
of the descriptive design 
(i.e. without control group) 
Excluded studies: 
8 for including historical controls 
4 for including patients without 
histological diagnosis 
1 for including previously published data 
1 for not testing all patients 
1 for using PCR only as testing method 
Studies on LP prevalence in HCV+ 
patients = 27 
Studies = 11 
Studies included in the 
systematic review = 6 
16 studies were excluded because 
of the descriptive design 
(i.e. without control group) 
Excluded studies: 
3 for different study design 
2 for for including patients without 
histological diagnosis 
Reports identified searching the three databases (November 2007) 
Pubmed             =    295 
EMBASE             =    308 
CINAHL             =    21 
SCOPUS             =    398 
Other              =     6 
Total (excluding overlapping references)   =    447 
Figure 1 Flow diagram
Lichen planus and HCV infection
G Lodi et al
604
Oral Diseases
Meta-analysis. The total number of patients of the
included studies was 5404. In ﬁve studies no seropos-
itive patients were found in either group. In these
studies OR could not be calculated. The proportion of
HCV-positive subjects was higher in the lichen planus
group compared with controls in all the other studies
but two, the OR of HCV seropositivity in patients
with LP varying between 0.23 (95% CI: 0.01–5.85)
and 15.94 (95% CI: 2.00–127.22). The summary
estimate OR for all studies was 4.85 (95% CI: 3.58–
6.56) (Figure 2), showing a statistically signiﬁcant
diﬀerence in the proportion of HCV seropositive
subjects among lichen planus patients, compared with
controls. Interestingly, despite the high geographical
variety, heterogeneity of the results was not signiﬁcant
(I2 = 10.7%).
Subgroup analysis. In 11 studies all patients included
had oral lesions (with and without cutaneous lesions),
also in this subgroup, HCV seroprevalence was signif-
icantly more common among LP patients than controls
(OR= 5.56 95% CI: 3.50–8.81). The summary esti-
mate OR increased considerably in the Mediterranean
studies (OR= 6.99 95% CI: 4.92–9.94), while, in the
studies from Northern Europe, halved, becoming not
signiﬁcant (OR= 2.14 95% CI: 0.59–7.69). The sum-
Table 2 Characteristics of the studies included in the meta-analysis investigating HCV prevalence in lichen planus patients
Country Reference
Lichen planus
group Control group Serological tests
Risk of
biasn Oral lesions n Provenience Screening Conﬁrmatory
Brazil Issa et al, 1999 34 9 ⁄ 34 60 Blood donors ELISA 3 Unspeciﬁed High
France Cribier et al, 1994 52 4 ⁄ 52 112 Dermatology patients ELISA 2 RIBA 2 Moderate
Dupin et al, 1997 102 102 ⁄ 102 306 Surgical patientsa ELISA 3 RIBA 3 Moderate
Egypt Ibrahim et al, 1999 43 Unspeciﬁed 30 Dermatology patients Unspeciﬁed Unspeciﬁed High
Germany Imhof et al, 1997 84 45 ⁄ 84 87 Dermatology patients ELISA 2 RIBA 2 High
India Das et al, 2006 104 Unspeciﬁed 150 HIV negative outpatients ELISA 3 Unspeciﬁed High
Iran Ghaderi et al, 2007 73 Unclear 150 Blood donors ELISA 3 High
Rahnama et al, 2005 66 Unclear 140 Blood donors ELISA RIBA 2 High
Israel Yarom et al, 2007 62 62 ⁄ 62 62 Patients with other oral
conditionsb
ELISA 3 RIBA 3 Low
Italy Carrozzo et al, 1996 70 70 ⁄ 70 70 Patients with other oral
conditionsc
ELISA 2 RIBA 2 Low
Serpico et al, 1997 100 100 ⁄ 100 100 Dental patients ELISA 2 RIBA 2 Moderate
Mignogna et al, 1998 263 263 ⁄ 263 100 Dental patients ELISA 2 RIBA 2 High
Lodi et al, 2004 303 303 ⁄ 303 278 Dental patients ELISA 3 Line immunoassy Low
Japan Tanei et al, 1995 45 37 ⁄ 45 45 Surgical patients
(orthopedic)
ELISA 2 Unspeciﬁed Moderate
Mexico Luis-Montoya et al,
2005
36 Unclear 60 Blood donors ELISA 3 Unspeciﬁed High
Nepal Garg et al, 2002 86 29 ⁄ 86 43 Unknown ELISA 3 –e Moderate
Nigeria Daramola et al, 2002 57 Unspeciﬁed 48 Healthy and
dermatology patients
ELISA 2 Unspeciﬁed Moderate
Saudi
Arabia
Alı` et al, 2007 40 40 ⁄ 40 40 Dental patients ELISA 3 Unspeciﬁed Moderate
Serbia Bokor-Bratic et al, 2004 48 48 ⁄ 48 60 Dental patients ELISA 4 Unspeciﬁed Low
Spain Santander et al, 1994 50 Unspeciﬁed 27 Dermatology patients ELISA 2 PCR High
Gimenez-Arnau et al,
1995
25 Unspeciﬁed 18 Unknown Unspeciﬁed Unspeciﬁed High
Sanchez Perez et al, 1996 78 56 ⁄ 78 82 Dermatology patients ELISA 2 Unspeciﬁed Low
Bagan et al, 1998 100 100 ⁄ 100 100 Healthy subjects ELISA 2 RIBA 2 or 3 Moderate
Gimenez-Garcia et al,
2003
101 53 ⁄ 101 99 Dermatology patients ELISA 2 RIBA 2 Low
Thailand Klanrit et al, 2003 60 60 ⁄ 60 60 Dental health care workers ELISA 3 RNA High
Turkey Ilter et al, 1998 75 Unspeciﬁed 75 Dermatology patients Unspeciﬁed –e Moderate
Kirtak et al, 2000 73 27 ⁄ 73 73 Dermatology patientsd ELISA 3 Unspeciﬁed Moderate
Erkek et al, 2001 52 7 ⁄ 52 54 Dermatology patients ELISA 3 Unspeciﬁed Low
Harman et al, 2004 128 52 ⁄ 128 128 Healthy subjects ELISA 3 Unspeciﬁed Low
UK Ingafou et al, 1998 55 55 ⁄ 55 110 Dental health care workers ELISA 3 –e High
Tucker et al, 1999 45 13 ⁄ 45 32 Dermatology patients ELISA 2 RIBA 3 Low
USA Bellman et al, 1995 30 Unspeciﬁed 41 Dermatology patients ELISA 2 RIBA 2 Moderate
Beaird et al, 2001 24 Unspeciﬁed 20 Dermatology patients
(psoriasis)
Unspeciﬁed Unspeciﬁed High
aExcluding patients with hepatic diseases, receiving haemodialysis and transplant patients.
bHyperkeratosis, oral candidiasis, recurrent aphthous stomatitis, pemphigus vulgaris, mucous membrane pemphigoid, benign oral growth.
cLeukoplakia, frictional keratosis, verrucous carcinoma, nicotinic stomatitis, white spongious nevus.
dExcluding patients with porphyria cutanea tarda, cutaneous vaculitis and prurigo.
eAll subjects were negative.
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mary estimate OR of studies from US was similar to
the global one (OR= 5.09; 95% CI: 1.33–19.41)
whereas the corresponding ﬁgure for Africa was even
lower than in Northern Europe (OR= 1.65; 95% CI:
0.69–3.95). The pooling data of studies with a LP
group with a mean age of 50 years or less showed that
even in LP groups of younger age, the frequency of
HCV seropositivity was signiﬁcatively higher than in
control groups (OR= 3.43 95% CI: 2.02–5.85).
Only 12 of the studies included in the meta-analysis
clearly ruled out the possibility of a drug-induced
lichenoid reaction but the OR still indicated a signiﬁcant
higher risk of HCV seropositivity in LP than in controls
(3.91; 95% CI: 2.17–7.04) (Figure 3). Similarly, when we
considered studies i including a conﬁrmatory HCV test
further to the screening one, the OR was close to the
global one (4.76; 95% CI: 3.07–7.41).
Sensitivity test and publication bias. When studies with
high and moderate risk of bias were excluded from all
the meta-analysis the summary estimate did not change
signiﬁcantly (Figure 4). The visual examination of the
symmetry of the funnel plot did not suggest large
publication bias (Figure 5).
LP prevalence among HCV patients
From the articles resulting from the diﬀerent search
strategies, 27 potentially eligible studies were identiﬁed,
16 were excluded because they had no control group
(descriptive design), three for the diﬀerent study design
and clinical diagnosis and two for lack of histological
diagnosis (Figure 1).
Characteristics of the included studies. The main charac-
teristics of the 6 included studies are presented in
Table 3. Two studies were from Brazil, and one each
from France, Poland, Spain and Turkey. The control
group was enrolled among dental patients in 3 studies, in
two cases among healthy subjects and in one case among
HCV-, HBV- and HIV- liver disease patients. In all
studies HCV status was detected by ELISA and then
conﬁrmed by PCR or RIBA.
Critical appraisal of the included studies. On the basis of
the criteria previously described, two studies resulted at
low risk of bias, two were judged at moderate risk of
bias, and two at high risk of bias. Only two studies
clearly stated that the study group was formed by
consecutive patients (Table 3).
Meta-analysis. The total number of patients of the
included studies was 2197. In all six studies the
prevalence of LP was higher among HCV-positive
subjects compared with controls, the OR varying
between 1.42 (95% CI: 0.13–15.94) and 7.43 (95% CI:
2.36–23.42). The summary estimate OR for all studies
was 4.47 (95% CI: 1.84–10.86) (Figure 6), showing a
statistically signiﬁcant diﬀerence in the proportion of LP
prevalence among HCV-positive subjects, compared
with controls. As for the previous analysis, despite high
geographical variety, heterogeneity of the results was
not signiﬁcant (I2 = 0%).
Only three out of six studies (Bagan et al, 1998;
Figueiredo et al, 2002; Cunha et al, 2005) reported
detailed data on anti-HCV treatments. In 2 studies
Study or subgroup
Lichen planus Controls Odds ratio Odds ratio
Events EventsTotal Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
Ali 2007
Garg 2002
llter 1998
Ingafou 1998
Bokor Bratic 2004
Tucker 1999
Rahnama 2005
Daramola 2002
Cribier 1994
Dupin 1997
Ibrahim 1999
Yarom 2007
Issa 1999
Beaird 2001
Erkek 2001
Gimenenz Garcia 2003
Luis Montoya 2005
Kirtak 2000
Bagan 1998
Serpico 1997
Bellman 1995
Ghaderi 2007
Lodi 2004
Das 2006
Carrozzo 1996
Harman 2004
Tanei 1995
Klanrit 2003
Sanchezperez 1996
Mignogna 1998
Gimenez Arnau 1995
Imhof 1997
Santander 1994
Total (95% CI) 2544 2860 100.0% 4.85 [3.58, 6.56]
Total events
Heterogeneity: Tau2 = 0.07; Chi2 = 30.23, df = 27 (P = 0.30); I2 = 11%
Test for overall effect: Z = 10.24 (P < 0.00001)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
9
2
2
2
2
2
8
9
3
3
3
6
3
14
3
9
9
3
3
150
60
128
18
87
27
82
70
278
45
100
2
4
7
9
1
5
523
36
7
3
58
2
19
8
17
4
16
76
11
13
19
372 79
40 40
43
75
110
60
32
140
48
112
306
30
62
60
20
54
99
60
73
100
100
150
41
64
75
55
48
45
66
57
52
102
43
62
34
24
54
101
36
73
100
100
30
73
303
104
70
128
45
60
78
263
25
84
50
0.9%
1.7%
6.1%
2.6%
8.5%
4.1%
1.7%
1.7%
3.2%
3.4%
0.9%
1.8%
7.1%
1.5%
10.2%
3.1%
1.7%
11.7%
1.0%
4.9%
2.0%
4.6%
1.0%
3.6%
5.5%
1.8%
2.0%
2.0%
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(Figueiredo et al, 2002; Cunha et al, 2005), 37.5% of the
patients with LP were previously exposed to IFN-a
whereas the third study (Bagan et al, 1998) speciﬁcally
stated that no signiﬁcant diﬀerences were observed in
the incidence of OLP between those patients who
received interferon and those who did not.
Subgroup analysis. LP frequency was signiﬁcantly higher
among HCV-positive patients than controls either in
Europe (OR = 4.26 95% CI: 1.13–16.10) or in Brazil
(OR = 4.73 95% CI: 1.55–14.42).
Sensitivity test. When studies with high and moderate
risk of bias were excluded from the meta-analysis the
summary estimate was still statistically signiﬁcant
(OR = 6.97 95% CI: 2.16–22.52).
The visual examination of the symmetry of the funnel
plot did not suggest large publication bias.
Discussion
In this systematic review we ﬁrmly conﬁrm the associa-
tion between HCV infection and LP. According to the
meta-analysis, the summary estimate of OR showed that
LP patients have about a ﬁve fold higher risk than the
controls of being HCV seropositive and the OR for
exclusive OLP was not substantially diﬀerent from the
global one. Moreover, quite the same OR was found
analysing the prevalence of LP among patients with CLD
due to HCV infection. However, the data showed a
marked study and geographical variability, with the
relationship between HCV and LP being prevalent in
Japan,Mediterranean countries and theUSA. This ﬁgure
explains the strong regional connotation of the associa-
tion among LP and HCV infection that was observed
mainly in Southern Europe where HCV is highly
prevalent. Interestingly, a similar geographic variability
has been demonstrated for other EHM linked to HCV
infection, such as porphyria cutanea tarda, lymphoma
and even mixed cryoglobulinemia (Gisbert et al, 2003;
Dal and Franceschi, 2006; Cohen Tervaert et al, 2007).
Several factors could be potentially responsible for the
observed variability in results. These may include
misclassiﬁcation of LP, the highly variable prevalence
of HCV infection across the world, diﬀerences in the
viral characteristics of HCV, diﬀerences in genetic
Study or subgroup
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susceptibility to HCV-induced LP, variability in the
studies design and biases.
To avoid misclassiﬁcation of LP, we decided to
include in the meta-analysis only studies in which the
clinical diagnosis of LP was conﬁrmed histologically.
Some studies have shown variability in both interob-
server and intraobserver reliability in the clinicopatho-
logical assessment mainly of OLP (van der Meij and van
der Waal I, 2003). However, a histological conﬁrmation
of the clinical diagnosis is worldwide accepted as a gold-
standard practice in both LP and OLP studies.
Several medications including IFN-a and ribavirin
can trigger mucocutaneous lichenoid reactions (McCar-
tan and McCreary, 1997; Berk et al, 2007). However,
IFN-a has been reported to have also no inﬂuence
(Pawlotsky et al, 1995b) or even to ameliorate LP
(Doutre et al, 1992; Strumia et al, 1993; Hildebrand
et al, 1995; Pedersen, 1998)both clinically and histolog-
ically (Nagao et al, 1999). If lichenoid drug reactions are
misdiagnosed and included in the samples of those
with LP, it would result in an overestimation of the
association between LP and HCV. Only a minority of
the studies included in the meta-analysis stated clearly
that a diagnosis of lichenoid reaction was excluded but
when they were analysed together a signiﬁcant increased
risk of being HCV-seropositive in LP patients was still
found. Regarding speciﬁcally the anti-HCV treatment,
while in some HCV-infected patients the lichenoid
lesions could be secondary to anti-HCV therapy (Giu-
liani et al, 2007), it is unlikely that in the majority of the
published studies most of the patients were exposed to
antiviral treatments. Signiﬁcantly, in the largest pub-
lished study on EHM in HCV-infected patients (not
included in the meta-analysis because the clinical diag-
nosis was not histologically conﬁrmed in all the patients)
showing a signiﬁcant association between LP and HCV
infection (El-Serag et al, 2002), less than 5% of 32.204
studied patients received antiviral therapies. In an
another study (Bagan et al, 1998), no signiﬁcant
diﬀerences in the frequency of OLP were observed
between patients who received interferon-alpha (IFN-a)
and those who did not.
Even if this meta-analysis highlighted a signiﬁcant
diﬀerence between Northern and Southern Europe, the
pooled data from African studies with the highest HCV
prevalence in the general population did not show a
signiﬁcant association (Ibrahim et al, 1999; Daramola
et al, 2002). This suggests that any LP-HCV association
Table 3 Characteristics of the studies included in the meta-analysis investigating lichen planus prevalence in HCV positive patients
Country Reference
HCV subjects Controls
Risk of
biasn Characteristics
Serological tests
n ProvenienceScreening Conﬁrmatory
Brazil Figueiredo et al, 2002 126 Consecutive patients with
HCV diagnosis
ELISA 2 RNA 898 Dental patients Low
Cunha et al, 2005 134 Patients with other viral
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ELISA 3 RNA 95 Dental patients Moderate
France Cribier et al, 1998 81 HIV and HBV DNA
excluded
ELISA 3 RNA 50 HCV-, HBV- and
HIV- liver
disease patients
Low
Poland Sulka et al, 2006 39 23 chronic hepatitis and 16
chirrosis
ELISAa RIBAa 29 Dental patients High
Spain Bagan et al, 1998 505 From Hepatology Unit ELISAa RIBAa 100 Healthy controls High
Turkey Dervis and Serez, 2005 70 Co-existent liver disease and
treatment with antiviral or
immunomodulatory agents
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ELISAa RNAa 70 Healthy controls Moderate
aNot otherwise speciﬁed.
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cannot be only explained on the basis of HCV
endemicity. Indeed, the studies investigating the fre-
quency of LP among HCV-positive subjects showed
prevalences generally higher than expected, indepen-
dently of the geographical origin.
Viral factors (such as genotype or viral load) seem to
be ruled out by the observation that LP can be
associated world-wide with the same genotypes com-
monly found in patients without LP (Pawlotsky et al,
1995a; Lodi et al, 1997), though mainly genotype 1b
seems associated with LP, and it could be uncommon in
the UK (Harris et al, 1999).
Genetic diﬀerences among diﬀerent populations
should be also taken into account. HCV-related OLP
appears associated mainly with the HLA-DR6 allele in
Italy (Carrozzo et al, 2001) whereas it does not in UK
(Carrozzo et al, 2005). However, a comparison study of
the OLP-positive ⁄HCV-positive group with an OLP-
negative ⁄HCV-positive group is necessary to ultimately
test this plausible hypothesis.
Some controversial data could have being caused by
the small cohort size in a number of studies. Indeed, the
majority of the studies included less than 100 subjects.
As a result some studies, mainly coming from countries
with low prevalence of HCV infection (Ilter et al, 1998;
Ingafou et al, 1998; Garg et al, 2002; Bokor-Bratic,
2004; Laeijendecker et al, 2005; Ali and Suresh, 2007)
showed the lack of any case or control positive to HCV
serology. In those cases, the key question is whether the
power of such studies was suﬃcient to detect any
diﬀerence in the prevalence of HCV. For example, in
one of the above studies, performed in Netherlands
(Laeijendecker et al, 2005), 100 patients with OLP and
100 controls were recruited. Considering a prevalence of
HCV infection in Netherlands of 0.5% (Van der Poel et
al, 1991) and estimated risk of three (in this meta-
analysis the odd ratio of being HCV infected in lichen
planus patients from Northern Europe was 2.14), the
power of such a study is only 20% (with an alpha error
of 0.05, two tales). To obtain an acceptable power of
80%, more than 400 patients and 400 controls should
have been recruited.
Age is a possible confounder because, in many popu-
lations, the prevalence of HCV exposure varies in
diﬀerent age groups (Alter, 2007), and older individuals
have a higher prevalence of LP. However, the meta-
analysis seems to confute the hypothesis that the high
frequency of HCV seropositivity found in LP groups is
caused by the increased prevalence of HCV infection in
elderly patients (Campisi et al, 2004). Indeed, the
subgroup analysis of studies with LP patients £50 years
still showed a signiﬁcant association with HCV infection.
Given the design of most of the case-control and
cohort studies published, it is impossible to establish
whether the HCV exposure occurred before or after the
onset of LP. As a result, HCV-infected patients might
have an increased risk of developing LP or conversely,
patients with LP could have an enhanced risk of HCV
infection. A very recent epidemiologic study from
Japan suggests that OLP prevalence in HCV-infected
patients increased signiﬁcantly as the subjects grew older
(Nagao et al, 2007) suggesting that the patients are very
likely ﬁrst infected with HCV and only later develop LP.
This prospective study suggests also that the duration of
the infection should be a potential source of heteroge-
neity in the published studies. Moreover, in countries
where the prevalence among the LP-free subjects is low,
the spread of the virus might be recent and not yet
produced full consequences on LP development. Thus,
in countries with a very low prevalence of HCV, LP
should be probably better identiﬁed in HCV-infected
patients rather than seeking to ﬁnd HCV infection in LP
patients (Carrozzo, 2001). Notably, in this meta-analysis
we could not include any study looking for LP in
chronic HCV infected from countries with low HCV
prevalence. It has to be considered, however, that such a
study could possibly require the recruitment of a large
number of patients for being signiﬁcant making it very
diﬃcult on a practical base and possibly clinically
negligible.
Clinical implications of the results presented in this
systematic review are particularly relevant. A high
proportion of patients aﬀected by HCV-associated
chronic hepatitis may have persistently normal amino-
transferase levels and recent data suggest that only a
minority of people with HCV in Europe are aware of
their infection (Merkinaite et al, 2008), thus testing for
HCV patients with LP can lead to the diagnosis of a
condition for which treatments are available and pre-
cautions can be useful to avoid further spread. More-
over, because chronic HCV infection can lead to
cirrhosis and hepatocellular carcinoma (Eisen et al,
2005; Alter, 2007) and OLP is a potentially malignant
disorder, an early diagnosis and a proper management
might save lives and being beneﬁcial in reducing health
care costs.
In conclusion, this systematic review and meta-anal-
ysis shows that LP may be signiﬁcantly associated with
HCV infection mainly in Mediterranean countries, in
Japan and USA. All the sub-analyses and the sensitivity
assessments done strongly and consistently suggest this
possible association. Because the HCV can replicate in
the skin and in the oral mucosa and HCV-speciﬁc T cells
have been found in OLP specimen (Carrozzo et al, 2002;
Pilli et al, 2002), the virus could be involved in the
pathogenesis of at least some OLP cases, probably via
an immunological pathway still to be deﬁned.
Finally, some of the controversial epidemiological
data published could have been inﬂuenced by method-
ological biases (such as misclassiﬁcation of the disease,
small sample size, and recent acquisition of HCV, etc.)
further to a generic geographic eﬀect linked to world-
wide HCV prevalence.
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